Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Engerix-B Challenge Dose 20 Years Post-Primary Vaccination
NCT00456625Phase 4Completed
- Sponsor
- GSK
- Start
- Apr 2007
- Primary completion
- Jan 2008
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hepatitis b vaccine recombinant in hepatitis B (HBV), sponsored by GSK. Primary endpoint: Number of Participants With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Specific Cut-off Values at 1 month. Started Apr 2007; status: completed.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00456625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00456625.